ID: ALA3888274
Type: Binding
Description: DAO Inhibition Assay: Recombinant human DAO (2.4 μg/mL) was used as source of DAO enzyme activities. The assay was performed as described in the method for human SSAO/VAP-1 (Example 5) except the substrate used was 200 μM putrescine, and the control wells contained 10 μM aminoguanidine instead of Mofegiline: Briefly, in a standard 96 well plate assay 50 μL of purified human SSAO/VAP-1 (0.25 μg/mL) in 0.1 M NaPO4 buffer (pH 7.4) was added into each well. Test compounds were dissolved in DMSO and tested in a Concentration Response Curve (CRC) with 4-9 data points, typically in the micromolar or nanomolar range after incubation with human SSAO/VAP-1 for 30 min at 37 °C. After 30 min incubation, 50 μL of the reaction mixture containing 600 μM benzylamine (Sigma Aldrich), 120 μM Amplex Red (Sigma Aldrich) and 1.5 U/mL horseradish peroxidase (Sigma Aldrich) prepared in 0.1 M NaPO4 buffer (pH 7.4) were added to the corresponding well. The fluorescence unit (RFU) was read every 2.5 min for 30 min at 37 °C. excitation 565 nm and emission 590 (Optima; BMG labtech). The slope of the kinetics for each well was calculated using MARS data analysis software (BMG labtech) and this value was used to deduce the IC50 value (Dotmatics).
Bioactivity
Activity Types for Assay ALA3888274
IC50
Parent Molecular Weight | ALogP | Polar Surface Area |
---|---|---|
197.23 | 2.57 | 2.57 |
252.29 | 1.58 | 1.58 |
252.29 | 1.58 | 1.58 |
302.37 | 1.56 | 1.56 |
331.18 | 2.34 | 2.34 |
288.34 | 1.18 | 1.18 |
280.34 | 2.41 | 2.41 |
280.34 | 2.41 | 2.41 |
224.24 | 0.98 | 0.98 |
286.73 | 2.23 | 2.23 |
274.32 | 0.79 | 0.79 |
260.29 | 0.52 | 0.52 |
238.26 | 1.24 | 1.24 |
266.32 | 1.89 | 1.89 |
288.34 | 1.18 | 1.18 |
224.24 | 0.98 | 0.98 |
260.29 | 0.52 | 0.52 |
274.32 | 0.79 | 0.79 |
288.34 | 1.13 | 1.13 |
302.37 | 1.56 | 1.56 |
288.34 | 1.13 | 1.13 |
280.34 | 2.36 | 2.36 |
282.31 | 1.59 | 1.59 |
270.28 | 1.72 | 1.72 |